1. Himsworth HP. Diabetes mellitus: its differentiation into insulin-sensitive and insulin insensitive types. Lancet 1936;1:117.
2. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993;328:676–685.
3. Panzram G. Mortality and survival in type 2 (non–insulin-dependent) diabetes mellitus. Diabetologia 1987;30:123–131.
4. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735–744.
5. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 1998;28:518–524.
6. King H, Rewers M, WHO Ad Hoc Diabetes Reporting Group. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 1993;16:157–177.
7. Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997;46:791–810.
8. Diabetes in special populations. In: Harris M, Cowie C, Stern M, eds. Diabetes in America, 2nd ed. National Institutes of Health Publication No 95–1468. Bethesda, MD: National Institutes of Health, 1995: 613–702.
9. Barnett AH, Eff C, Leslie RDG, et al. Diabetes in identical twins. Diabetologia 1981;20:87–93.
10. Lindgren CM, Hirschhorn JN. The genetics of type 2 diabetes. Endocrinologist 2001;11:178–187.
11. Stoffel M, Froguel P, Takeda J, et al. Human glucokinase gene: isolation, characterization, and identification of two missense mutations linked to early-onset non–insulin-dependent (type 2) diabetes mellitus. Proc Natl Acad Sci USA 1992;89:7698–7702.
12. Altshuler D, Hirschhorn J, Klannemark M, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2. Nat Genet 2000;26:76–80.
13. Rewers M, Hamman R. Risk factors for non–insulin-dependent diabetes. In: Harris M, ed. Diabetes in America, 2nd ed. National Institutes of Health Publication No. 95–1468. Bethesda, MD: National Institutes of Health, 1995:79–230.
14. Colditz G, Willett W, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122;481–486.
15. Manson JE, Nathan DM, Krolewski AS, et al. A prospective study of exercise and incidence of diabetes among US male physicians. JAMA 1992;268:63–67.
16. vanDam R, Rimm EB, Willett WC, et al. Dietary pattern and risk for type 2 diabetes mellitus in U.S. men. Ann Intern Med 2002;136: 201–209.
17. Hu FB, Leitzman MF, Stampfer M, et al. Physical activity and television watching in relation to risk of type 2 diabetes mellitus in men. Arch Intern Med 2001;161:1542–1548.
18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–1197.
19. Coustan D, Carpenter M, O’Sullivan P, et al. Gestational diabetes: predictors of subsequent disordered glucose metabolism. Am J Obstet Gynecol 1993;168:1139–1145.
20. Knowler WC, Narayan KVM, Hanson RL, et al. Preventing non–insulin-dependent diabetes mellitus. Diabetes 1995;44:483–488.
21. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001;345:790–797.
22. DeFronzo RA. The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988;37:667.
23. Leahy JL. Natural history of β-cell dysfunction in NIDDM. Diabetes Care 1990;13:992.
24. DeFronzo RA. The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988;37:667–687.
25. Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976;42:222.
26. Pimenta W, Korytkowski M, Mitrakou A, et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose tolerant individuals with a first-degree NIDDM relative. JAMA 1995;273:1855.
27. O’Rahilly S, Turner RC, Matthews DR. Impaired pulsatile secretion of insulin in relatives of patients with non–insulin dependent diabetes. N Engl J Med 1988;318:1225.
28. Del Prato S, Leonetti F, Simonson D, et al. Effect of sustained physiologic hyperinsulinemia and hyperglycemia on insulin secretion and insulin sensitivity in man. Diabetologia 1994;37:1025–1035.
29. DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 1993;329:978–986.
30. Diabetes Prevention Program Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999;22:623–634.
31. DPP Research Group. The Diabetes Prevention Program: reduction in the incidence of type 2 diabetes with lifestyle modification or metformin. N Engl J Med 2002;346:393–403.
32. Diabetes Prevention Program Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 2000;23:1619–1629.
33. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350.
34. Chiasson J-L, Josse RG, Gorris R, et al. for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002;359:2072–2077.
35. Pan X-R, Li G-W, Hu Y-H, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care 1997;20:537–544.
36. Step by step: eating to lower your high blood cholesterol. Bethesda, MD: National Heart, Lung, and Blood Institute Information Center, 1987.
37. Buchanan TA, Xiang HA, Peters RK, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high risk Hispanic women. Diabetes 2002;51:2796–2803.